Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Herceptin trastuzumab: Phase II; Marketed as first line therapy in combination with paclitaxel and as a single agent in second and third line therapy

Of 114 women with previously untreated HER2-positive metastatic breast

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE